MCID: PDT014
MIFTS: 38

Pediatric Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases

Aliases & Classifications for Pediatric Ependymoma

MalaCards integrated aliases for Pediatric Ependymoma:

Name: Pediatric Ependymoma 12 15
Childhood Ependymoma 12
Familial Ependymoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5509
NCIt 50 C8578
UMLS 73 C1851584

Summaries for Pediatric Ependymoma

MalaCards based summary : Pediatric Ependymoma, also known as childhood ependymoma, is related to ependymoma and intestinal neuroendocrine benign tumor. An important gene associated with Pediatric Ependymoma is MEN1 (Menin 1), and among its related pathways/superpathways is Chks in Checkpoint Regulation. The drugs Cisplatin and Vincristine have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and bone, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Pediatric ependymomas are similar in nature to the adult form of ependymoma in that they are thought to... more...

Related Diseases for Pediatric Ependymoma

Diseases related to Pediatric Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 ependymoma 10.5
2 intestinal neuroendocrine benign tumor 10.0 BCAT1 MEN1
3 small intestine neuroendocrine neoplasm 10.0 BCAT1 MEN1
4 malignant ependymoma 9.9 ERCC5 LOXL3
5 malignant glioma 9.8
6 glioma 9.8
7 benign ependymoma 9.8
8 xeroderma pigmentosum, variant type 9.7 APEX1 ERCC5

Graphical network of the top 20 diseases related to Pediatric Ependymoma:



Diseases related to Pediatric Ependymoma

Symptoms & Phenotypes for Pediatric Ependymoma

GenomeRNAi Phenotypes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

26 (show all 27)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.66 APEX1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.66 MEN1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.66 FBXW7
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.66 FBXW7 MEN1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.66 MEN1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.66 FBXW7
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.66 FBXW7
8 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.66 APEX1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.66 APEX1 FBXW7 MEN1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.66 FBXW7
11 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.66 APEX1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.66 APEX1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.66 FBXW7 MEN1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.66 MEN1
15 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.66 MEN1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.66 FBXW7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.66 APEX1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.66 MEN1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 9.65 LOXL3
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-145 9.65 BCAT1
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 9.65 BCAT1
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.65 BCAT1
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.65 BCAT1 LOXL3
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-204 9.65 BCAT1
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-22 9.65 BCAT1
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.65 BCAT1
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.65 BCAT1

MGI Mouse Phenotypes related to Pediatric Ependymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.77 APEX1 FBXW7 HEY2 LOXL3 MEN1
2 growth/size/body region MP:0005378 9.63 APEX1 ERCC5 FBXW7 HEY2 LOXL3 MEN1
3 craniofacial MP:0005382 9.62 FBXW7 HEY2 LOXL3 MEN1
4 digestive/alimentary MP:0005381 9.56 ERCC5 FBXW7 LOXL3 MEN1
5 liver/biliary system MP:0005370 9.35 APEX1 ERCC5 FBXW7 HEY2 MEN1
6 mortality/aging MP:0010768 9.1 APEX1 ERCC5 FBXW7 HEY2 LOXL3 MEN1

Drugs & Therapeutics for Pediatric Ependymoma

Drugs for Pediatric Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 210)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
2
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
3
Carboplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 41575-94-4 10339178 38904 498142
4
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
6
Thiotepa Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 52-24-4 5453
7
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
8
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1 135968-09-1
9
Temozolomide Approved, Investigational Phase 3,Phase 1,Phase 2 85622-93-1 5394
10
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
11
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 1177-87-3
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-02-2 5743
15
Valproic Acid Approved, Investigational Phase 2, Phase 3,Phase 1 99-66-1 3121
16
Histamine Approved, Investigational Phase 3,Phase 2 51-45-6, 75614-87-8 774
17
Cyproheptadine Approved Phase 3,Phase 2 129-03-3 2913
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
19 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
20 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
21 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
24 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
25 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
26 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
28 Folic Acid Antagonists Phase 3,Phase 2,Phase 1,Not Applicable
29 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
30 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
31 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
32 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Folate Phase 3,Phase 2,Phase 1,Not Applicable
34 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
35 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
36 Keratolytic Agents Phase 3,Phase 2
37 Podophyllotoxin Phase 3,Phase 2 518-28-5
38 Gastrointestinal Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Antiemetics Phase 3,Phase 1
40 Autonomic Agents Phase 3,Phase 1
41 BB 1101 Phase 3,Phase 2,Phase 1
42 Peripheral Nervous System Agents Phase 3,Phase 1
43 Emetics Phase 3
44 Central Nervous System Depressants Phase 2, Phase 3,Phase 1
45 Neurotransmitter Agents Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1
46 GABA Agents Phase 2, Phase 3,Phase 1
47 Anticonvulsants Phase 2, Phase 3,Phase 1
48 Tranquilizing Agents Phase 2, Phase 3,Phase 1
49 Antimanic Agents Phase 2, Phase 3,Phase 1
50 Psychotropic Drugs Phase 2, Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 113)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
3 An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
4 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
5 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
6 Etoposide in Treating Young Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
7 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
8 High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
9 Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
10 Everolimus for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
11 Combination Chemotherapy Followed by Radiation Therapy in Treating Children With Localized Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
12 Oxaliplatin in Treating Children With Recurrent or Refractory Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor Completed NCT00047177 Phase 2 Oxaliplatin
13 Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
14 Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
15 Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Completed NCT01462695 Phase 2 Sunitinib Malate
16 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
17 Irinotecan in Treating Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
18 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
19 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
20 Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors Completed NCT00005952 Phase 1, Phase 2 temozolomide
21 Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Primitive Neuroectodermal Tumors Completed NCT00003846 Phase 2 carboplatin;cyclophosphamide;thiotepa;vincristine sulfate
22 Phenylacetate in Treating Children With Recurrent or Progressive Brain Tumors Completed NCT00003241 Phase 2 phenylacetate
23 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
24 Docetaxel in Treating Children With Recurrent Solid Tumors Completed NCT00002825 Phase 2 docetaxel
25 Vinorelbine in Treating Children With Recurrent or Refractory Cancers Completed NCT00003234 Phase 2 vinorelbine tartrate
26 Lobradimil and Carboplatin in Treating Children With Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
27 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
28 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin
29 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
30 Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
31 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
32 Temozolomide Followed by Radiation Therapy in Treating Children With Newly Diagnosed Malignant CNS Tumors Completed NCT00005955 Phase 2 temozolomide
33 Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Recruiting NCT02684071 Phase 2 Intra thecal methotrexate;topotecan;cyclophosphamide
34 Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03526250 Phase 2 Palbociclib
35 PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03213678 Phase 2 PI3K/mTOR Inhibitor LY3023414
36 Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Recruiting NCT03233204 Phase 2 Olaparib
37 Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Recruiting NCT03213704 Phase 2 Larotrectinib
38 Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Recruiting NCT03210714 Phase 2 Erdafitinib
39 Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting NCT03155620 Phase 2 Ensartinib;Erdafitinib;Larotrectinib;Olaparib;Palbociclib;PI3K/mTOR Inhibitor LY3023414;Selumetinib Sulfate;Tazemetostat;Ulixertinib;Vemurafenib
40 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
41 Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Active, not recruiting NCT00788125 Phase 1, Phase 2 carboplatin;dasatinib;etoposide phosphate;ifosfamide
42 Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma Active, not recruiting NCT00602667 Phase 2 Induction Chemotherapy;Low-Risk Therapy;High-Risk Therapy;Intermediate-Risk Therapy
43 Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Suspended NCT03213665 Phase 2 Tazemetostat
44 Erlotinib Versus Oral Etoposide in Patients With Recurrent or Refractory Pediatric Ependymoma Terminated NCT01032070 Phase 2 erlotinib;etoposide
45 Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205 Terminated NCT01247922 Phase 2 Erlotinib
46 Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma Terminated NCT01088035 Phase 2 Carboplatin
47 TP-38 Toxin in Treating Young Patients With Recurrent or Progressive Supratentorial High-Grade Glioma Terminated NCT00074334 Phase 1, Phase 2
48 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor Withdrawn NCT00003273 Phase 2 carboplatin;cisplatin;cyclophosphamide;etoposide;leucovorin calcium;methotrexate;temozolomide;thiotepa;vincristine sulfate
49 Erlotinib Alone or in Combination With Radiation Therapy in Treating Young Patients With Refractory or Relapsed Malignant Brain Tumors or Newly Diagnosed Brain Stem Glioma Unknown status NCT00360854 Phase 1 erlotinib hydrochloride
50 Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors Unknown status NCT00007813 Phase 1 carboplatin;cyclophosphamide;etoposide

Search NIH Clinical Center for Pediatric Ependymoma

Genetic Tests for Pediatric Ependymoma

Anatomical Context for Pediatric Ependymoma

MalaCards organs/tissues related to Pediatric Ependymoma:

41
Brain, Liver, Bone, Small Intestine

Publications for Pediatric Ependymoma

Articles related to Pediatric Ependymoma:

(show all 41)
# Title Authors Year
1
Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology. ( 29774098 )
2018
2
Imaging biomarkers of outcome after radiotherapy for pediatric ependymoma. ( 29500084 )
2018
3
Pediatric ependymoma: current treatment and newer therapeutic insights. ( 30418040 )
2018
4
Radical, Staged Approach to Extensive Posterior Fossa Pediatric Ependymoma: 3-Dimensional Operative Video. ( 29029279 )
2017
5
Outcomes following proton therapy for pediatric ependymoma. ( 29239262 )
2017
6
Prognostic relevance of miR-124-3p and its target TP53INP1 in pediatric ependymoma. ( 28437838 )
2017
7
Pediatric Ependymoma: A Proteomics Perspective. ( 28387652 )
2017
8
The Pediatric Ependymoma Protein Database (PEPD). ( 29124086 )
2017
9
Current Clinical Challenges in Childhood Ependymoma: A Focused Review. ( 28640697 )
2017
10
Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study. ( 27287856 )
2016
11
Re-irradiation of recurrent pediatric ependymoma: modalities and outcomes: a twenty-year survey. ( 27386327 )
2016
12
Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma. ( 27104090 )
2016
13
Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study. ( 25724157 )
2015
14
Overcoming Chemoresistance of Pediatric Ependymoma by Inhibition of STAT3 Signaling. ( 26500028 )
2015
15
Pediatric Ependymoma. ( 26503805 )
2015
16
Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells. ( 25120190 )
2014
17
Emotional and behavioral functioning after conformal radiation therapy for pediatric ependymoma. ( 24462384 )
2014
18
Endoscopic endonasal transclival approach to a ventral pontine pediatric ependymoma. ( 23992235 )
2013
19
PI3K pathway activation provides a novel therapeutic target for pediatric ependymoma and is an independent marker of progression-free survival. ( 24077346 )
2013
20
Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. ( 21627842 )
2011
21
Apurinic/apyrimidinic endonuclease is inversely associated with response to radiotherapy in pediatric ependymoma. ( 21207372 )
2011
22
Super-selective basilar artery infusion of bevacizumab and cetuximab for multiply recurrent pediatric ependymoma. ( 22192550 )
2011
23
Dosimetric effect of setup motion and target volume margin reduction in pediatric ependymoma. ( 20347495 )
2010
24
Telomerase inhibition as a novel therapy for pediatric ependymoma. ( 20184588 )
2010
25
Pediatric ependymoma: biological perspectives. ( 19531565 )
2009
26
Identification of novel chromosomal abnormalities and prognostic cytogenetics markers in intracranial pediatric ependymoma. ( 18179864 )
2008
27
Contribution of NMR spectroscopy to the differential diagnosis of a recurrent cranial mass 7 years after irradiation for a pediatric ependymoma. ( 16708251 )
2006
28
Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3. ( 15701279 )
2005
29
Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. ( 15050308 )
2004
30
Childhood ependymoma: a systematic review of treatment options and strategies. ( 12895136 )
2003
31
Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. ( 12505253 )
2002
32
Cervical subluxation after surgery and irradiation of childhood ependymoma. ( 12006754 )
2002
33
Current management of childhood ependymoma. ( 12108890 )
2002
34
Commentary (Paulino): Current Management of Childhood Ependymoma. ( 28776322 )
2002
35
Commentary (Cohen/Glod): Current Management of Childhood Ependymoma. ( 28776323 )
2002
36
Chromosome arm 6q loss is the most common recurrent autosomal alteration detected in primary pediatric ependymoma. ( 10451703 )
1999
37
Clinical manifestations of childhood ependymoma: a multitude of syndromes. ( 9693331 )
1998
38
Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. ( 9215786 )
1997
39
Cytogenetic t(11;17)(q13;q21) in a pediatric ependymoma. Is 11q13 a recurring breakpoint in ependymomas? ( 1581886 )
1992
40
Adjunctive treatment for recurrent childhood ependymoma of the IV ventricle: chemotherapy with CDDP and MCNU. ( 2383872 )
1990
41
Multiple chromosome rearrangements in a childhood ependymoma. ( 3203296 )
1988

Variations for Pediatric Ependymoma

Expression for Pediatric Ependymoma

Search GEO for disease gene expression data for Pediatric Ependymoma.

Pathways for Pediatric Ependymoma

Pathways related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.41 APEX1 ERCC5 FBXW7

GO Terms for Pediatric Ependymoma

Cellular components related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.35 APEX1 ERCC5 FBXW7 HEY2 MEN1
2 nuclear chromosome, telomeric region GO:0000784 8.62 APEX1 MEN1

Biological processes related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription, DNA-templated GO:0045892 9.61 HEY2 LOXL3 MEN1
2 cellular response to DNA damage stimulus GO:0006974 9.54 APEX1 ERCC5 MEN1
3 Notch signaling pathway GO:0007219 9.46 FBXW7 HEY2
4 DNA repair GO:0006281 9.43 APEX1 ERCC5 MEN1
5 lung development GO:0030324 9.4 FBXW7 LOXL3
6 vasculogenesis GO:0001570 9.32 FBXW7 HEY2
7 response to UV GO:0009411 9.16 ERCC5 MEN1
8 negative regulation of Notch signaling pathway GO:0045746 8.96 FBXW7 HEY2
9 cellular response to peptide hormone stimulus GO:0071375 8.62 APEX1 MEN1

Molecular functions related to Pediatric Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 9.37 ERCC5 MEN1
2 nuclease activity GO:0004518 9.32 APEX1 ERCC5
3 protein N-terminus binding GO:0047485 9.26 ERCC5 MEN1
4 endonuclease activity GO:0004519 9.16 APEX1 ERCC5
5 protein binding, bridging GO:0030674 8.96 FBXW7 MEN1
6 endodeoxyribonuclease activity GO:0004520 8.62 APEX1 ERCC5

Sources for Pediatric Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....